Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study

Summary: This phase 2 study investigates first-line benmelstobart plus anlotinib and chemotherapy in human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced/metastatic gastric or gastroesophageal junction (G/GEJ) cancer. Twenty-five eligible patients receive benmelstob...

Full description

Bibliographic Details

Main Authors:	Liangyu Bie, Chen Wei, Suxia Luo, Shuailei Dong, Zhiwei Gu, Yijie Ma, Qingxin Xia, He Zhang, Jing Li, Wenying Deng, Ning Li
Format:	Artigo
Language:	Inglês
Published:	Elsevier 2025-06-01
Series:	Cell Reports Medicine
Subjects:	benmelstobart plus anlotinib and chemotherapy HER2-negative G/GEJ phase 2 study first-line therapy PD-L1 PBIC profile
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666379125002186
Tags:	Add Tag No Tags, Be the first to tag this record!